Company Description

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products.

Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.

The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021.

Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Indaptus Therapeutics, Inc.

Country	United States
Founded	2000
Industry	Biotechnology
Sector	Healthcare
Employees	5
CEO	Junyi Dai

Contact Details

Address: Three Columbus Circle, 15th Floor New York, New York 10019 United States
Phone	646 427 2727
Website	indaptusrx.com

Stock Details

Ticker Symbol	INDP
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	1857044
CUSIP Number	45339J204
ISIN Number	US45339J2042
Employer ID	86-3158720
SIC Code	2834

Key Executives

Name	Position
Junyi Dai	Chief Executive Officer and Chairman
Dr. Michael J. Newman Ph.D.	Founder, Chief Scientific Officer and Director
Walt Addison Linscott Esq.	Chief Operating Officer
Yu Ding	Chief Financial Officer

Latest SEC Filings

Date	Type	Title
Apr 24, 2026	8-K/A	[Amend] Current report
Apr 23, 2026	8-K	Current Report
Apr 6, 2026	SCHEDULE 13G/A	Filing
Apr 3, 2026	8-K	Current Report
Mar 30, 2026	SCHEDULE 13D	Filing
Mar 24, 2026	8-K	Current Report
Mar 24, 2026	SCHEDULE 13D/A	Filing
Mar 17, 2026	10-K	Annual Report
Mar 2, 2026	SCHEDULE 13D	Filing
Feb 27, 2026	8-K	Current Report

View All SEC Filings